GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2...

Area of Science:

• Immunotherapy
• Hematopoietic Stem Cell Transplantation
• Oncology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
• Graft-versus-host disease (GVHD) and relapse remain significant challenges post-HSCT.
• Granulocyte-macrophage colony-stimulating factor (GVAX) vaccine aims to enhance immune responses to reduce relapse risk.

Purpose of the Study:

• To evaluate the efficacy and safety of GVAX vaccination administered early after allogeneic HSCT for patients with MDS or relapsed/refractory AML.
• To determine if GVAX impacts survival, relapse rates, and GVHD incidence.

Main Methods:

• A randomized, placebo-controlled, phase 2 trial involving 57 patients who received GVAX or placebo post-HSCT.
• Vaccinations were initiated between day 30-45 post-engraftment, with tacrolimus and methotrexate for GVHD prophylaxis.
• Outcomes including progression-free survival, overall survival, relapse incidence, and GVHD were assessed with a median follow-up of 39 months.

Main Results:

• No significant differences were observed in 18-month progression-free survival (53% vs 55%), overall survival (63% vs 59%), or relapse incidence (30% vs 37%) between GVAX and placebo groups.
• GVAX was associated with more injection site reactions, but no grade 3+ vaccine-related adverse events.
• Immune cell reconstitution and key immune biomarkers showed no significant differences between the groups.

Conclusions:

• Early administration of GVAX after HSCT for MDS/AML does not improve survival outcomes.
• The GVAX vaccine was generally well-tolerated but did not demonstrate clinical benefit in this patient population.
• Further research may explore alternative immunotherapy strategies post-HSCT.